201 Mission Street Suite 2375
141 articles with Jaguar Health
Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16
Jaguar Health, Inc. (NASDAQ:JAGX) announced today announced that Lisa Conte, Jaguar's founder, president and CEO, will present at the virtual 2020 H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020, at 3:00 p.m. Eastern Time.
Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
Jaguar Health, Inc.today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the "Company") have jointly entered into a third amendment to the accounts receivable purchase agreement with Oasis Capital
Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants
Jaguar announced today the launch of its mental health Entheogen Therapeutics Initiative (ETI) that aims to discover and develop groundbreaking, novel, natural medicines derived from psychoactive plants for treatment of mood disorders, neuro-degenerative diseases, addiction, and other mental health disorders.
Amount Exceeds Minimum Stockholders' Equity Requirement for Initial Listing on The Nasdaq Capital Market
Jaguar Health, Inc. today provided updates regarding ongoing investigator-initiated trials in non-HIV patient populations of crofelemer (Mytesi®), the novel FDA-approved plant-based oral drug developed and marketed by Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
Jaguar Health Submits Final Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) the last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs.
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., have jointly entered into a second amendment to the accounts receivable purchase agreement with Oasis Capital, LLC dated May 12, 2020, pursuant to which Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company.
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated second quarter 2020 financial results.
Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials and Business Updates
Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrhea
Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea
Jaguar Health, Inc. announced the activation of the investigational new drug (IND) application filed by the Company's wholly owned subsidiary Napo Pharmaceuticals, Inc. ("Napo") with the FDA for the use of crofelemer (Mytesi®) for prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.
Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera
Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the 28-day preclinical toxicology and safety study in rats began yesterday to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals
Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Special Meeting of Stockholders of the Company (the "Special Meeting") that was held on July 21, 2020.
FDA Invites Jaguar Health to Expedite Submission of Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) the second-to-last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™
Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea
A significant proportion of patients undergoing cancer therapy experience diarrhea.
Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) the final major regulatory filing to support approval of its oral plant-based drug candidate Canalevia™
Canalevia would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea
On World Rainforest Day, Jaguar Health Reinforces Commitment to Amazon Rainforest and Sustainable Harvesting Programs for Plant-based Pharmaceuticals
Jaguar Health, Inc.'s (NASDAQ:JAGX) chief of sustainability and ethnobotanist Steven King, Ph.D. was featured on Forest Trends' Viewpoints, discussing the ancient and powerful medicinal knowledge of Indigenous peoples and local communities in the Amazon Rainforest, the importance of understanding, respecting and conserving this vast body of wisdom along with the rainforests, and the pioneering fair-trade tree-to-bottle development of Mytesi
Jaguar Health, Inc. announced the voting results from the Annual Meeting of Stockholders of the Company that was held on May 15, 2020.
Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC
Net proceeds to the Company from the Registered Direct Offering are approximately $0.49 million, which Jaguar intends to use for the ongoing commercialization of Mytesi, the Company’s lead prescription drug product, and for working capital and general corporate purposes.
Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8M
The average monthly Mytesi sales from August through October of this year increased over 50% relative to average monthly Mytesi® sales that took place from January through July of 2017.
The call is being hosted to review year-to-date sales figures for Jaguar and Napo Pharmaceuticals.